HR+/HER2- Breast Cancer Market Set To Triple

The HR-positive/HER2-negative breast cancer market is set to more than triple in value by 2022, according to a new forecast by Datamonitor Healthcare. The growth will be driven by a marketed product as well as the approval of several late-phase pipeline candidates. Generic and biosimilar drugs are expected to offset these sales from the beginning of 2023.